• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600530.SS
Share

Shanghai Jiaoda Onlly Co.,Ltd Stocks

CN¥ 5.19Last Updated 14.07.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

CN¥ 610.70M

CN¥ 5.19
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shanghai Jiaoda Onlly Co., Ltd., together with its various subsidiaries, primarily operates within China's health food sector. The company's product portfolio is extensive, featuring functional health items, probiotics, traditional tonics, dietary supplements, and natural extracts, alongside a range of disinfection solutions. Beyond health-related products, the firm is also engaged in the wholesale and retail distribution of pharmaceutical goods, as well as the production and sale of other food products. Further diversifying its operations, Shanghai Jiaoda Onlly provides road cargo and transportation services, in addition to offering travel agency activities. Headquartered in Shanghai, China, this company was founded in 1990.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 00:57

Biogen shares fell after disappointing data on its Alzheimer's drug

14.07.2026 23:31

Software developers' stocks plummeted following IBM's warning. What's wrong with the sector?

14.07.2026 23:07

Goldman Sachs set a new record for equity trading revenue. Its stock price soared

14.07.2026 22:06

Apple shares received a rare "sell" recommendation. An analyst identified risks to demand

14.07.2026 21:33

SpaceX will become the internet provider for Frontier flights. Why this matters

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026